Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models

Manja Friese-Hamim, Giuseppe Locatelli, Friedhelm Bladt

Cancer Res (2016) 76 (14_Supplement): 4663.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4663

Published: 15 July 2016

View article

Journal Articles

Abstract 2591: Activity of MSC2156119J in non-small cell lung cancer models with activating EGFR mutation

Friedhelm Bladt, Manja Friese-Hamim, Andree Blaukat

Cancer Res (2015) 75 (15_Supplement): 2591.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2591

Published: 01 August 2015

View article

Journal Articles

Abstract 4510: Model-based phase II dose selection of c-Met inhibitor MSC2156119J

Wenyuan Xiong, Samer El Bawab, Friedhelm Bladt, Michael Meyring, Manfred Klevesath, Gerald Falchook, David Hong, Andreas Johne, Pascal Girard

Cancer Res (2015) 75 (15_Supplement): 4510.

DOI: https://doi.org/10.1158/1538-7445.AM2015-4510

Published: 01 August 2015

View article

Journal Articles

Abstract 1911: High MET and CA9 expressions define a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis candidates for MET inhibition strategy

Annemilai Tijeras-Raballand, Cindy Neuzillet, Miguel Albuquerque, Nathalie Colnot, Friedhelm Bladt, Manfred Klevesath, Christian Ihling, Hongxia Zheng, Maryse Baia, Christiane Copie-Bergman, Eric Raymond, Armand de Gramont, Valérie Paradis, Sandrine Faivre

Cancer Res (2015) 75 (15_Supplement): 1911.

DOI: https://doi.org/10.1158/1538-7445.AM2015-1911

Published: 01 August 2015

View article

Journal Articles

Abstract 2724: Development of a sensitive assay for measuring pharmacodynamic modulation of c-Met in biopsies

Friedhelm Bladt, Frank Jaehrling, Manja Friese-Hamim, Gerald S. Falchook, Hesham M. Amin, Manfred B. Klevesath, Andree Blaukat

Cancer Res (2014) 74 (19_Supplement): 2724.

DOI: https://doi.org/10.1158/1538-7445.AM2014-2724

Published: 01 October 2014

View article

Journal Articles

Abstract 4706: Biomarker selection defines a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis who are candidates for MET inhibition strategy

Annemilai Tijeras-Raballand, Miguel Albuquerque, Cindy Neuzillet, Nathalie Colnot, Friedhelm Bladt, Christian Ihling, Manfred Klevesath, Hongxia Zheng, Eric Raymond, Armand de Gramont, Sandrine Faivre, Valérie Paradis

Cancer Res (2014) 74 (19_Supplement): 4706.

DOI: https://doi.org/10.1158/1538-7445.AM2014-4706

Published: 01 October 2014

View article

Journal Articles

Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial

Gerald S. Falchook, David S. Hong, Hesham M. Amin, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku, J. Gabrielle Granda, HongXia Zheng, Manfred B. Klevesath, Karola Köhler, Friedhelm Bladt, Andreas Johne, Razelle Kurzrock

Cancer Res (2014) 74 (19_Supplement): CT236.

DOI: https://doi.org/10.1158/1538-7445.AM2014-CT236

Published: 01 October 2014

View article

Journal Articles

Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.

Friedhelm Bladt, Andree Blaukat, Dieter Dorsch, Manja Friese-Hamim, Michael Meyring, Oliver Schadt

Cancer Res (2013) 73 (8_Supplement): 925.

DOI: https://doi.org/10.1158/1538-7445.AM2013-925

Published: 15 April 2013

View article

Journal Articles

Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants

Yitzhak Zimmer, Benoît Pochon, Deborah M. Stroka, Daniel M. Aebersold, Andree Blaukat, Friedhelm Bladt, Michaela Medová

Cancer Res (2012) 72 (8_Supplement): 1786.

DOI: https://doi.org/10.1158/1538-7445.AM2012-1786

Published: 15 April 2012

View article

Journal Articles

Abstract 1787: The c-Met inhibitors EMD 1214063 and EMD 1204831 are effective in combination with EGFR and VEGF inhibitors in NSCLC models

Friedhelm Bladt, Andree Blaukat, Dieter Dorsch, Manja Friese-Hamim, Michael Meyring, Oliver Schadt, Frank Stieber

Cancer Res (2012) 72 (8_Supplement): 1787.

DOI: https://doi.org/10.1158/1538-7445.AM2012-1787

Published: 15 April 2012

View article

Journal Articles

Abstract 2786: Identification and preclinical characterization of EMD 1204831 – A selective c-Met kinase inhibitor in clinical phase 1

Friedhelm Bladt, Andree Blaukat, Dieter Dorsch, Claus Fittschen, Manja Friese-Hamim, Ulrich Graedler, Christine Knuehl, Michael Meyring, Oliver Schadt, Frank Stieber

Cancer Res (2011) 71 (8_Supplement): 2786.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2786

Published: 15 April 2011

View article

Journal Articles

Abstract 5777: EMD 1214063, an exquisitely selective c-Met kinase inhibitor in clinical phase 1

Oliver Schadt, Friedhelm Bladt, Andree Blaukat, Dieter Dorsch, Manja Friese-Hamim, Claus Fittschen, Ulrich Graedler, Michael Meyring, Wilfried Rautenberg, Frank Stieber, Claudia Wilm

Cancer Res (2010) 70 (8_Supplement): 5777.

DOI: https://doi.org/10.1158/1538-7445.AM10-5777

Published: 15 April 2010

View article

Journal Articles

Abstract 3622: Preclinical characterization of EMD1214063, a potent and highly selective inhibitor of the c-Met kinase in Phase I clinical trials

Friedhelm Bladt, Andree Blaukat, Dieter Dorsch, Claus Fittschen, Manja Friese-Hamim, Ulrich Graedler, Michael Meyring, Wilfried Rautenberg, Oliver Schadt, Frank Stieber

Cancer Res (2010) 70 (8_Supplement): 3622.

DOI: https://doi.org/10.1158/1538-7445.AM10-3622

Published: 15 April 2010

View article

Journal Articles

Broad spectrum of antitumor activity of aflibercept (VEGF Trap) in tumor-bearing mice.

Marielle Chiron, Pascale Lejeune, Friedhelm Bladt, Patricia Vrignaud, Marie-Christine Bissery.

Cancer Res (2008) 68 (9_Supplement): 380.

Published: 01 May 2008

View article

Journal Articles

In vivo pre-clinical evaluation of the IGF-1R-specific antibody AVE1642 as single agent and in combination with Velcade ^® /Bortezomib

Friedhelm Bladt, Patricia Vrignaud, Stephane Guerif, Noelle Boussac, Thomas Chittenden, Thierry Hercend, Marielle Chiron, Marie-Christine Bissery

Cancer Res (2007) 67 (9_Supplement): 4115.

Published: 01 May 2007

View article

Journal Articles

Pre-clinical evaluation of the anti-tumor activity of the IGF1R - specific anitbody AVE1642

Friedhelm Bladt, Patricia Vrignaud, Marielle Chiron, Corinne Venot, Laurent Debussche, Rajeeva Singh, Thomas Chittenden, Thierry Hercend, Marie-Christine Bissery

Cancer Res (2006) 66 (8_Supplement): 289–290.

Published: 15 April 2006

View article

NARROW

Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models

Abstract 2591: Activity of MSC2156119J in non-small cell lung cancer models with activating EGFR mutation

Abstract 4510: Model-based phase II dose selection of c-Met inhibitor MSC2156119J

Abstract 1911: High MET and CA9 expressions define a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis candidates for MET inhibition strategy

Abstract 2724: Development of a sensitive assay for measuring pharmacodynamic modulation of c-Met in biopsies

Abstract 4706: Biomarker selection defines a subgroup of hepatocellular carcinoma (HCC) patients with poor prognosis who are candidates for MET inhibition strategy

Abstract CT236: MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial

Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.

Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants

Abstract 1787: The c-Met inhibitors EMD 1214063 and EMD 1204831 are effective in combination with EGFR and VEGF inhibitors in NSCLC models

Abstract 2786: Identification and preclinical characterization of EMD 1204831 – A selective c-Met kinase inhibitor in clinical phase 1

Abstract 5777: EMD 1214063, an exquisitely selective c-Met kinase inhibitor in clinical phase 1

Abstract 3622: Preclinical characterization of EMD1214063, a potent and highly selective inhibitor of the c-Met kinase in Phase I clinical trials

Broad spectrum of antitumor activity of aflibercept (VEGF Trap) in tumor-bearing mice.

In vivo pre-clinical evaluation of the IGF-1R-specific antibody AVE1642 as single agent and in combination with Velcade ^® /Bortezomib

Pre-clinical evaluation of the anti-tumor activity of the IGF1R - specific anitbody AVE1642

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only